Education
About Us
Working with TipRanks
Follow Us
Vaxart (VXRT)
OTHER OTC:VXRT
VXRT Stock Chart & Stats
$0.36
-$0.02(-2.57%)
At close: 4:00 PM EST
$0.36
-$0.02(-2.57%)
Day’s Range― - ―
52-Week Range$0.26 - $0.90
Previous CloseN/A
Volume1.40M
Average Volume (3M)479.81K
Market Cap
$93.51M
Enterprise Value$73.69M
Total Cash (Recent Filing)$28.79M
Total Debt (Recent Filing)$15.44M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Mar 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding240,069,840
10 Day Avg. Volume576,925
30 Day Avg. Volume479,815
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.48
Price to Sales (P/S)11.24
P/FCF Ratio-7.12
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda-1.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Vaxart News
VXRT FAQ
What was Vaxart’s price range in the past 12 months?
Vaxart lowest stock price was $0.26 and its highest was $0.90 in the past 12 months.
What is Vaxart’s market cap?
Vaxart’s market cap is $93.51M.
When is Vaxart’s upcoming earnings report date?
Vaxart’s upcoming earnings report date is Mar 19, 2026 which is in 70 days.
How were Vaxart’s earnings last quarter?
Vaxart released its earnings results on Nov 13, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.03.
Is Vaxart overvalued?
According to Wall Street analysts Vaxart’s price is currently Overvalued.
Does Vaxart pay dividends?
Vaxart pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart dividends here
What is Vaxart’s EPS estimate?
Vaxart’s EPS estimate is -0.05.
How many shares outstanding does Vaxart have?
Vaxart has 240,069,840 shares outstanding.
What happened to Vaxart’s price movement after its last earnings report?
Vaxart reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 10.959%.
Which hedge fund is a major shareholder of Vaxart?
Currently, no hedge funds are holding shares in VXRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
VXRT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.61%
12-Months-Change
Fundamentals
Return on Equity
-106.52%
Trailing 12-Months
Asset Growth
25.39%
Trailing 12-Months
Company Description
Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
VXRT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a significant partnership with Dynavax, which boosts financial stability and validates Vaxart's technology. Positive developments in the norovirus program and increased revenue are notable. However, the stop work order from BARDA and delays in norovirus trials present challenges.View all VXRT earnings summariesTechnical Analysis
Atossa Therapeutics
―
Karyopharm Therapeutics
―
Pliant Therapeutics
―
Repare Therapeutics
―
Kalaris Therapeutics
―
Ownership Overview
2.62% Insiders
<0.01% Mutual Funds
0.10% Other Institutional Investors
97.27% Public Companies and
Individual Investors